Glycan Therapeutics: Resurrecting an Almost Pharma‐Forgotten Drug Class

Posted on August 24, 2018

Despite their enormous potential, glycans as therapeutics yet remain a widely untapped drug class. This overview shares the viewpoint that glycans have been aptly termed the “dark matter” of biology and have thus been largely ignored for decades. Provided herein is a background on the multiple structures and functions of glycan therapeutics, and focuses on examples and case studies of the glycan therapeutics in clinical use or in a clinical development. Perspectives on various hurdles are also provided, such as regulatory or scientific messaging and how these can influence the clinical development of this drug category. Finally some of the necessary changes in perception, education, and research infrastructure for continued support and advancement of this promising category of therapeutics are described. – Full Article Link

Anti-Fibrotic Effect of SB-030 and Implications for Peripheral Vein Graft Bypass

Posted on March 14, 2018

2018 Keystone Symposium, Vascular Biology and Human Diseases: From Molecular Pathways to Novel Therapeutics, Poster Presentation – PDF Download

Targeting the Vessel Wall During Vascular Intervention with SB-030 Prevents Platelet Activation and Subsequent Neointimal Hyperplasia

Posted on September 21, 2017

ESC (European Society of Cardiology) Congress 2017 Poster Presentation – PDF Download

Sustained Efficacy of Intra-Articular SB-061, a Novel Matrix Regulator Inspired by Aggrecan, in a Rat Model of Osteoarthritis

Posted on March 14, 2018

2017 ACR/ARHP Annual Meeting (American College of Rheumatology) Poster Presentation – PDF Download

Interfering With Local Fibrotic Platelet Activation Significantly Inhibits Fibrosis in Multiple Animal Models

Posted on May 3, 2018

International Liver Congress 2018 “Best of ILC 2018” Summary Slide – PDF Download